Acrivon Therapeutics

ACRVNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$92.135 M

$2.15 +6.97%

Close of 22 Sept 2026

Revenue

—

Not reported

Earnings

-$77.9M

Loss-making

Shares outstanding

42,853,362

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#311Citius OncologyCTOR$99.5M
#312Anixa BiosciencesANIX$97.0M
#313Acrivon TherapeuticsACRV$92.1M
#314Oncolytics BiotechONCY$91.0M
#315RallybioRLYB$89.9M

What if Acrivon Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$705,521.54

Per share 328,150× higher

Bitcoin $1.74T

$40,642.20

Per share 18,903× higher

Nvidia $5.52T

$128,712.59

Per share 59,866× higher

Or at a round number

$200.0M $500.0M $1.00B $2.00B

Where these numbers come from

Share counts and financials for Acrivon Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.